期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

埃索美拉唑三联疗法治疗Hp阳性十二指肠球部溃疡60例疗效观察 被引量：1

下载PDF
导出
摘要 幽门螺杆菌（Hp）感染是消化性溃疡（PU）最重要的致病因子。目前对Hp阳性PU患者的基本治疗策略是在以PPI为基础的1周三联疗法根除Hp后，继续用3周PPI以确保溃疡愈合和症状缓解。本文观察埃索美拉唑1周三联短程疗法对Hp阳性十二指肠球部溃疡的临床疗效。
作者 石国庆 黄芸 王红 吴会超
机构地区 遵义医学院附属医院消化科
出处 《贵州医药》 CAS 2007年第3期245-246,共2页 Guizhou Medical Journal
关键词 HP阳性十二指肠球部溃疡 埃索美拉唑 三联疗法 疗效观察 治疗 三联短程疗法 消化性溃疡 幽门螺杆菌
分类号 R573.105 [医药卫生—消化系统]
  • 相关文献

参考文献6

  • 1郑之田,段丽萍.消化性溃疡病[M].北京;人民卫生出版社,1998.491.
  • 2张万岱,萧树东,胡伏莲,林三仁,胡品津,刘文忠,王继德,徐智民.幽门螺杆菌若干临床方面的共识意见(2003·安徽桐城)[J].中华内科杂志,2004,43(4):316-317. 被引量：140
  • 3Castell DO,Kahrilas PJ,Richter JE,et al.Esomeprazole(40 mg)compared with lansoprazole(30 mg)in the treatment of erosive esophagitis[J].Am J Gastroenterol,2002,97:575-583.
  • 4Talley NJ,Lauritsen K,Tunturi-Hihnala H,et al.Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastrooesophageal reflux disease:a controlled trial of"on-demand"therapy for 6 months[J].Aliment Pharmacol Ther,2001,15:347-354.
  • 5湛先保,李兆申,程能能,杜奕奇,邹多武,尹宁,龚燕芳.埃索美拉唑对健康志愿者抑制胃泌酸的药效学研究[J].中华消化杂志,2004,24(12):711-714. 被引量：21
  • 6Tulassay Z,Kryszewski A,Dire P,et al.One week of treatment with esomeprszole-based triple therapy eradicates Helieobacter pylori and heals patients with duodenal ulcer disease[J].Eur J Gastroenterol Hepatol,2001,13(12):1 457-1 465.

二级参考文献13

  • 1Malfertheiner P, Megraud F, O′Morain C, et al. European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection: the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther,2002 ,16:167-180.
  • 2Wilder-Smith C, Rohss K, Claar-Nilsson C, et al. Esomeprazole 40 mg provides more effective acid control than rabeprazole 20 mg.Gut, 2000, 47(suppl 3) :A63.
  • 3Horai Y, Kimura M, Furuie H, et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP 2C19 genotypes. Aliment Pharmacol Ther, 2001, 15:793-803.
  • 4Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg)compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol, 2002, 97:575-583.
  • 5Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther, 2000, 14:1249-1258.
  • 6Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther, 2001, 15:1729-1736.
  • 7Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of ''on-demand'' therapy for 6 months. Aliment Pharmacol Ther, 2001, 15:347-354.
  • 8Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther, 2000,14: 861-867.
  • 9Tsuneoka T, Fukushima K, Matsuo Y, et al. Genotype analysis of the CYP 2C19 gene in the Japanese population. Life Sci, 1996,59:1711-1715.
  • 10Rohss K, Hasselgren G, Hedenstrom H. Effect of esomeprazloe 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci,2002,47: 954-958.

共引文献159

同被引文献10

引证文献1

二级引证文献10

贵州医药
2007年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部